Meningococcal Serogroup B
Conditions
Brief summary
The overall aim of this study is to determine if an accelerated Bexsero® (Multicomponent meningococcal B vaccine) schedule compared to a standard schedule is immunogenic, safe, and tolerable, in order to increase capacity for rapid outbreak control. In this pilot study no formal hypothesis is tested.
Detailed description
A pilot study to evaluate the feasibility of a rapid clinical trial at the time of a meningococcal B outbreak, comparing an accelerated schedule of 4CMen B (0, 3 weeks) to the 0, 2 months schedule, to determine if the more compressed schedule is immunogenic, safe and tolerable. A shorter schedule offers the potential benefit of more rapid direct and indirect protection, and use of fewer public health resources for implementation.
Interventions
Sponsors
University of British Columbia
University of Calgary
Université de Montréal
Dalhousie University
Canadian Immunization Research Network
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
17 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant is willing and able to give informed consent for participation in the trial. * Male or Female, aged 17 to 25 years. * Current or intended student at an educational setting in the 2015-2016 year. * Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study. * In the Investigator's opinion, is able and willing to comply with all trial requirements.
Exclusion criteria
* Significant renal or hepatic impairment. * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. * Participant in another research trial involving an investigational product or medical device in the prior 12 weeks. * Previous bacteriologically confirmed N. meningitidis disease. * Prior receipt of a meningococcal B vaccine * Hypersensitivity to any vaccine component of products used in this study (see product monographs) * Immunodeficiency or autoimmune disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immune responses to 4CMenB vaccine, as measured by human Serum Bactericidal Assay (hSBA | Baseline to day 180 | Immune responses will be measured: * Prior to 4CMenB vaccine (baseline) * To a single dose of 4CMenB vaccine 21 days post-immunization * 21 days after the second dose of an accelerated compared to a standard 4CMenB schedule * Six months after an accelerated 4CMenB vaccine schedule and a standard schedule |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of solicited general adverse events | Day 0-6 | The number of participants in each vaccine group with each symptom day 0 to 6 after vaccine will be summarized. Each vaccine participant will record if they had any symptoms (yes/no) and the severity (mild, moderate, or severe.) The following general AEs will be solicited: * Drowsiness * Fever * Nausea * Diarrhea * Vomiting * Generalized muscle aches |
| Number of unsolicited general adverse events | Day 0-21 | The number of participants in each vaccine group with each symptom day 0 to 21 after vaccine will be summarized. Each vaccine participant will record if they had any symptoms (yes/no) and the severity (mild, moderate, or severe.) |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 reported in the accelerated vaccine schedule compared to a standard schedule | From injection to Day 180 | — |
| Number of solicited local and systemic injections site reactions | Day 0-6 | The following local (injection-site) AEs will be solicited: * Pain at injection site * Redness at injection site * Swelling at injection site |
Countries
Canada
Outcome results
None listed